ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.62 Million EUR | 0.83% |
| 2022 | 4.58 Million EUR | 12286.49% |
| 2021 | 37 Thousand EUR | 164.29% |
| 2020 | 14 Thousand EUR | 300.0% |
| 2019 | -7000.00 EUR | -100.86% |
| 2018 | 815 Thousand EUR | 128.93% |
| 2017 | 356 Thousand EUR | 135.76% |
| 2016 | 151 Thousand EUR | -33.77% |
| 2015 | 228 Thousand EUR | 239.62% |
| 2014 | 67.13 Thousand EUR | -10.33% |
| 2013 | 74.87 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 6.78 Million EUR | 0.0% |
| 2023 Q2 | 2.24 Million EUR | 0.0% |
| 2023 FY | 4.62 Million EUR | 0.83% |
| 2023 Q4 | 2.24 Million EUR | 0.0% |
| 2022 Q2 | 2.22 Million EUR | 0.0% |
| 2022 Q4 | 2.24 Million EUR | 0.0% |
| 2022 FY | 4.58 Million EUR | 12286.49% |
| 2021 FY | 37 Thousand EUR | 164.29% |
| 2021 Q2 | - EUR | 0.0% |
| 2021 Q4 | - EUR | 0.0% |
| 2020 Q2 | - EUR | 0.0% |
| 2020 Q4 | 14 Thousand EUR | 0.0% |
| 2020 FY | 14 Thousand EUR | 300.0% |
| 2019 Q2 | 40 Thousand EUR | 0.0% |
| 2019 FY | -7000.00 EUR | -100.86% |
| 2019 Q4 | -47 Thousand EUR | 0.0% |
| 2018 FY | 815 Thousand EUR | 128.93% |
| 2018 Q4 | 323 Thousand EUR | 0.0% |
| 2018 Q2 | 492 Thousand EUR | 0.0% |
| 2017 FY | 356 Thousand EUR | 135.76% |
| 2017 Q4 | 352 Thousand EUR | 0.0% |
| 2017 Q2 | 4000.00 EUR | 0.0% |
| 2016 FY | 151 Thousand EUR | -33.77% |
| 2016 Q2 | 137 Thousand EUR | 0.0% |
| 2016 Q4 | 14 Thousand EUR | 0.0% |
| 2015 Q2 | 310 Thousand EUR | 0.0% |
| 2015 FY | 228 Thousand EUR | 239.62% |
| 2015 Q4 | -82 Thousand EUR | 0.0% |
| 2014 Q4 | 189 Thousand EUR | 199900.0% |
| 2014 FY | 67.13 Thousand EUR | -10.33% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 Q3 | 94.50 EUR | 0.0% |
| 2013 FY | 74.87 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 0.409% |
| Adocia SA | 2.15 Million EUR | -114.93% |
| Aelis Farma SA | 9.05 Million EUR | 48.962% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -46.652% |
| genOway Société anonyme | 20.04 Million EUR | 76.948% |
| IntegraGen SA | 12.53 Million EUR | 63.142% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -1440.159% |
| Neovacs S.A. | 533.41 Thousand EUR | -766.31% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -174.812% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -23243.1% |
| Sensorion SA | 4.74 Million EUR | 2.574% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -1459.405% |
| TME Pharma N.V. | 17 Thousand EUR | -27082.353% |
| Valbiotis SA | 4.73 Million EUR | 2.366% |
| TheraVet SA | 1.07 Million EUR | -328.642% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -156.722% |
| argenx SE | 1.13 Billion EUR | 99.593% |
| BioSenic S.A. | 543 Thousand EUR | -751.013% |
| Celyad Oncology SA | 102 Thousand EUR | -4430.392% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 98.072% |
| Genfit S.A. | 28.56 Million EUR | 83.823% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -121.418% |
| Innate Pharma S.A. | 51.9 Million EUR | 91.097% |
| Inventiva S.A. | 17.47 Million EUR | 73.56% |
| MaaT Pharma SA | 2.22 Million EUR | -107.406% |
| MedinCell S.A. | 9.16 Million EUR | 49.552% |
| Nanobiotix S.A. | 30.05 Million EUR | 84.626% |
| Onward Medical N.V. | 532 Thousand EUR | -768.609% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 67.439% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -107.499% |
| Oxurion NV | 263 Thousand EUR | -1657.034% |
| Pharming Group N.V. | 245.31 Million EUR | 98.116% |
| Poxel S.A. | 1.98 Million EUR | -133.266% |
| GenSight Biologics S.A. | 1.26 Million EUR | -264.72% |
| Transgene SA | 1.18 Million EUR | -290.287% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.912% |
| Valneva SE | 153.71 Million EUR | 96.994% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 227.652% |